Cargando…

MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients

PURPOSE: Chronic hepatitis B (CHB) and metabolic associated fatty liver disease (MAFLD) are both important public health problems. The effect of concomitant MAFLD on patients with CHB is still unclear. This study aimed to explore the influence of MAFLD on liver fibrosis and inflammation in CHB patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiaoman, Zhou, Jing, Wu, Lili, Zhu, Xiang, Deng, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898022/ https://www.ncbi.nlm.nih.gov/pubmed/35256849 http://dx.doi.org/10.2147/DMSO.S351492

Ejemplares similares

Study on Post-Treatment Relapse in HBeAg Positive CHB Patients
por: Lu, Junfeng, et al.
Publicado: (2015)

HBsAg Dampened STING Associated Activation of NK Cells in HBeAg-Negative CHB Patients
por: Zheng, Bingqing, et al.
Publicado: (2021)

Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN
por: Islam, Mojahidul, et al.
Publicado: (2023)

Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment
por: Yang, Jiezuan, et al.
Publicado: (2023)

Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
por: Winther, Thilde Nordmann, et al.
Publicado: (2013)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
por: Lim, Chee Kent, et al.
Publicado: (2006)

Noninvasive Biomarkers in Assessment of Liver Fibrosis in Patients with HBeAg Negative Chronic Hepatitis B
por: Dimzova, Marija, et al.
Publicado: (2018)

Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon‐α monotherapy
por: Shang, Hongyan, et al.
Publicado: (2022)

A nomogram based on HBeAg, AST, and age to predict non-minimal liver inflammation in CHB patients with ALT <80 U/L
por: Zhang, Lu, et al.
Publicado: (2023)

Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study
por: Li, Qiang, et al.
Publicado: (2017)

Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver
por: Bae, Sung Kwan, et al.
Publicado: (2012)

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore
por: Lacey, L F, et al.
Publicado: (2007)

Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro
por: Tacke, Frank, et al.
Publicado: (2012)

Is the function of the HBeAg really unknown?
por: Milich, David R.
Publicado: (2019)

HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis
por: Xie, Xiaoyu, et al.
Publicado: (2021)

Viral Biomarkers in Chronic HBeAg Negative HBV Infection
por: Hadziyannis, Emilia, et al.
Publicado: (2018)

Quantitative HBsAg: Not helpful to evaluate fibrosis in HBeAg-negative chronic hepatitis B patients
por: Loureiro, Dimitri, et al.
Publicado: (2019)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients
por: Wang, Yang, et al.
Publicado: (2022)

Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients
por: Fouad, Rabab, et al.
Publicado: (2020)

Correction: HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis
por: Xie, Xiaoyu, et al.
Publicado: (2022)

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
por: Yang, Song, et al.
Publicado: (2016)

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients
por: Yang, Jiezuan, et al.
Publicado: (2014)

Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China
por: Chen, Tianyan, et al.
Publicado: (2018)

Manifestations of Perihepatic Lymph Nodes in Acute Flare of Chronic Hepatitis B: Association with HBeAg Status and with HBeAg Seroconversion
por: Ko, Yen-Ling, et al.
Publicado: (2015)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
por: Song, Guangjun, et al.
Publicado: (2023)

Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B
por: Dimzova, Marija, et al.
Publicado: (2019)

A cautionary note to hepatitis B e antigen (HBeAg)‐negative test results in pregnant women in an area prevalent of HBeAg‐negative chronic hepatitis B
por: Chalid, Maisuri T., et al.
Publicado: (2022)

Relapse Rate and Associated-Factor of Recurrence after Stopping NUCs Therapy with Different Prolonged Consolidation Therapy in HBeAg Positive CHB Patients
por: Pan, Xingfei, et al.
Publicado: (2013)

PP-084 Early virologic response predicts therapeutic outcomes in adefovir-treated HBeAg-positive chronic hepatitis B (CHB) patients
por: Hou, J.L., et al.
Publicado: (2008)

Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg‐Negative CHB
por: Wübbolding, Maximilian, et al.
Publicado: (2020)

Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients
por: Ahmed, Fatima A., et al.
Publicado: (2019)

Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection
por: Su, Tung-Hung, et al.
Publicado: (2013)

HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History
por: Bonino, Ferruccio, et al.
Publicado: (2022)

Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis
por: Zheng, Rui-dan, et al.
Publicado: (2010)

Correlation Between HBsAg Quantitation and HBV DNA in HBeAg-Negative HBV/D Patients
por: Teriaky, Anouar, et al.
Publicado: (2013)

HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication
por: Praneenararat, Surat, et al.
Publicado: (2014)

Serum Alpha-Fetoprotein as a Predictor of Liver Fibrosis in HBeAg-Positive Chronic Hepatitis B Patients
por: Yang, Kai, et al.
Publicado: (2023)

Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis
por: Zhang, Zhan-qing, et al.
Publicado: (2019)

Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B
por: Montazeri, Ghodrat, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_q9aaati9u511u7do4ipc3m3r3i